Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

키워드

참고문헌 (35)

1. Gschwind A, "The discovery of receptor tyrosine kinases : targets for cancer therapy", Nat Rev Cancer, 4, pp.361~370 (2004)
2. Schafer M, "Cancer as an overhealing wound : an old hypothesis revisited", Nat Rev Mol Cell Biol, 9, pp.628~638 (2008)
3. Jo M, "Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells", J Biol Chem, 275, pp.8806~8811 (2000)
4. Ma PC, "MET receptor juxtamembrane exon 14 alternative spliced variant : novel cancer genomic predictive biomarker", Cancer Discov, 5, pp.802~805 (2015)
5. Sadiq AA, "MET as a possible target for non-smallcell lung cancer", J Clin Oncol, 31, pp.1089~1096 (2013)
6. Liu X, "A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3", Clin Cancer Res, 17, pp.7127~7138 (2011)
7. Beau-Faller M, "MET gene copy number in non-small cell lung cancer : molecular analysis in a targeted tyrosine kinase inhibitor naive cohort", J Thorac Oncol, 3, pp.331~339 (2008)
8. Onozato R, "Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers", J Thorac Oncol, 4, pp.5~11 (2009)
9. Onitsuka T, "Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status", J Thorac Oncol, 5, pp.591~596 (2010)
10. Park S, "MET amplification, protein expression, and mutations in pulmonary adenocarcinoma", Lung Cancer, 90, pp.381~387 (2015)
11. Comoglio PM, "Drug development of MET inhibitors : targeting oncogene addiction and expedience", Nat Rev Drug Discov, 7, pp.504~516 (2008)
12. Zou HY, "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms", Cancer Res, 67, pp.4408~4417 (2007)
13. Brandes F, "Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model", BMC Cancer, 15, pp.71~ (2015)
14. Frampton GM, "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors", Cancer Discov, 5, pp.850~859 (2015)
15. Bang YJ, "Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors", J Clin Oncol, 32(15 Suppl), pp.2520~ (2014)
16. Camaj P, "EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells", Biol Chem, 390, pp.1293~1302 (2009)
17. Yamamoto H, "PIK3CA mutations and copy number gains in human lung cancers", Cancer Res, 68, pp.6913~6921 (2008)
18. Fritsch C, "Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials", Mol Cancer Ther, 13, pp.1117~1129 (2014)
19. Lutterbach B, "Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival", Cancer Res, 67, pp.2081~2088 (2007)
20. Lennerz JK, "MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib", J Clin Oncol, 29, pp.4803~4810 (2011)
21. Egile C, "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in METamplified cancer", Mol Cancer Ther, 14, pp.384~394 (2015)
22. McDermott U, "Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency", Cancer Res, 70, pp.1625~1634 (2010)
23. Qi J, "Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors", Cancer Res, 71, pp.1081~1091 (2011)
24. Benderra MA, "Acquired EGFR mutation as the potential resistance driver to crizotinib in a MET-mutated tumor", J Thorac Oncol, 11, pp.e21~e23 (2016)
25. Kwak EL, "Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer", Cancer Discov, 5, pp.1271~1281 (2015)
26. Knowlden JM, "Elevated levels of epidermal growth factor receptor", c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells, 2003, pp.144, 1032~1044
27. Morgillo F, "Heterodimerization of insulin-like growth factor receptor", epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib, 2006, pp.66, 10100~10111
28. Tanizaki J, "Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification", Br J Cancer, 105, pp.807~813 (2011)
29. Zehir A, "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients", Nat Med, 23, pp.703~713 (2017)
30. Spoerke JM, "Phosphoinositide 3-kinase(PI3K)pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models", Clin Cancer Res, 18, pp.6771~6783 (2012)
31. Liu X, "Nextgeneration sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations", J Clin Oncol, 34, pp.794~802 (2016)
32. Hellman A, "A role for common fragile site induction in amplification of human oncogenes", Cancer Cell, 1, pp.89~97 (2002)
33. Piscitello D, "AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11", Oncogene, 37, pp.427~438 (2018)
34. Hata AN, "Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition", Nat Med, 22, pp.262~269 (2016)
35. Chabon JJ, "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients", Nat Commun, 7, pp.11815~ (2016)